最新の財務諸表(Form-10K)によると、Peijia Medical Limitedの総資産は$0で、純損失は$-226です。
PEJMFの主要な財務比率は何ですか?
Peijia Medical Limitedの流動比率は0、純利益率は-36.74、1株当たり売上高は$0.91です。
Peijia Medical Limitedの収益はセグメントまたは地域別にどのように分けられていますか?
Peijia Medical Limited の最大収益セグメントは Neurointerventional で、最新の利益発表における収益は 385,492,551 です。地域別に見ると、China が Peijia Medical Limited の主要市場であり、収益は 667,321,372 です。
Peijia Medical Limitedは収益を上げていますか?
いいえ、最新の財務諸表によると、Peijia Medical Limitedの純損失は$-226です。
Peijia Medical Limitedに負債はありますか?
いいえ、Peijia Medical Limitedの負債は0です。
Peijia Medical Limitedの発行済株式数は何株ですか?
Peijia Medical Limitedの総発行済株式数は0株です。
主要データ
前終値
$1.38
始値
$1.38
当日レンジ
$1.38 - $3.5
52週レンジ
$1.38 - $3.5
取引高
76.0K
平均取引高
0
配当利回り
--
1株当たり利益(TTM)
-0.11
時価総額
$924.5M
PEIJIA MEDICAL LIMITEDとは何ですか?
Peijia Medical Ltd. engages in the manufacture and sale of medical devices. The company is headquartered in Suzhou, Jiangsu and currently employs 1,035 full-time employees. The company went IPO on 2020-05-15. The firm primarily operates its businesses through two segments, Transcatheter Valve Therapeutic Business segment and Neurointerventional Business segment. Transcatheter Valve Therapeutic Business segment is mainly engaged in the business of research and development, manufacturing and sales of transcatheter valve therapeutic medical devices. Neurointerventional Business segment is mainly involved in the business of research and development, manufacturing and sales of neurointerventional procedural medical devices. The Company’s products include commercialized products such as TaurusOne and TaurusElite. The firm mainly conducts its businesses in the domestic market.